Repligen (RGEN) Reports In-Line Q4 EPS, provides guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
EPS Growth %: 0.0%
Financial Fact:
Investment income: 97K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Investment income: 97K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
(Updated - February 21, 2024 7:40 AM EST)
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $155.7 million versus the consensus estimate of $155.38 million.
GUIDANCE:
Repligen sees 2024 EPS of $1.42-$1.49, versus the consensus of $1.77. Repligen sees 2024 revenue of $620-650 million, versus the consensus of $660.7 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
